Page last updated: 2024-12-04

cotinine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Nicotianagenus[no description available]SolanaceaeA plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH]

Cross-References

ID SourceID
PubMed CID854019
CHEMBL ID578211
CHEBI ID68641
SCHEMBL ID49060
MeSH IDM0005249

Synonyms (136)

Synonym
(5s)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
BRD-K94144010-001-05-5
BRD-K94144010-001-04-8
brd-4010
brd4010
DIVK1C_000861
KBIO1_000861
SDCCGMLS-0066565.P001
(s)-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone
cotinine [inn]
nih 10498
cotinina [inn-spanish]
(s)-(-)-cotinine
ccris 7625
brn 0083099
cotininum [inn-latin]
(s)-cotinine
einecs 207-634-9
EU-0100285
(-)-cotinine, >=98%
SPECTRUM4_001793
SPECTRUM_001984
BSPBIO_002459
ACON1_000202
PRESTWICK_134
cotinine (-)
486-56-6
cas-486-56-6
SPECTRUM5_000465
BSPBIO_000004
IDI1_000861
PRESTWICK3_000082
MEGXP0_001870
PRESTWICK2_000082
cotinine
MLS001423950
smr000449278
(-)-cotinine
MLS000758262
KBIO2_002541
KBIO2_005109
KBIOSS_002550
KBIO2_007677
KBIO3_001679
KBIOGR_002368
SPECTRUM3_000700
SPBIO_001943
PRESTWICK1_000082
NINDS_000861
PRESTWICK0_000082
SPECTRUM1500208
BPBIO1_000006
LOPAC0_000285
HMS2091G22
C 5923
HMS2051A15
s(-)-1-methyl-5-(3-pyridyl)-2-pyrrolidone
NCGC00093739-08
BMSE000577
(s)-1-methyl-5-(3-pyridyl)-2-pyrrolidinone
chebi:68641 ,
CHEMBL578211
HMS1568A06
HMS1920A14
HMS3260J12
HMS2095A06
(5s)-1-methyl-5-(3-pyridyl)pyrrolidin-2-one
AKOS007930814
NCGC00254396-01
tox21_300615
A827581
(5s)-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone
(5s)-1-methyl-5-pyridin-3-yl-pyrrolidin-2-one
pharmakon1600-01500208
nsc-756704
nsc756704
tox21_111219
dtxcid9027576
dtxsid1047576 ,
HMS2232F15
S9339
CCG-100799
bdbm50370573
us8609708, 91 cotinine
cotinina
k5161x06ll ,
2-pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (5s)-
hsdb 7805
unii-k5161x06ll
5-24-02-00504 (beilstein handbook reference)
cotininum
AM20061246
LP00285
(5s)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one
(s)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one
SCHEMBL49060
NC00049
NCGC00093739-13
tox21_111219_1
cotinine [hsdb]
cotinine [mi]
nicotine impurity c [ep impurity]
nicotine ditartrate dihydrate impurity c [ep impurity]
nicotine resinate impurity c [ep impurity]
n-methyl-2-(3-pyridyl)-5-pyrrolidone
(-)-1-methyl-5-(3-pyridyl)-2-pyrrolidinone
CS-4787
NCGC00260970-01
tox21_500285
nicotine impurity c
HY-B1178
AB00053721_08
(-)-cotinine, analytical standard
nih-10498
(-)-cotinine, 98%
(5s)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one ((-)-cotinine)
(-)-cotinine 1.0 mg/ml in methanol
SR-01000075768-6
SR-01000075768-5
sr-01000075768
SR-01000075768-1
SBI-0050273.P003
BBL102262
STL556061
AS-50387
nicotine ep impurity c
Q421177
BRD-K94144010-001-09-7
SDCCGSBI-0050273.P004
NCGC00093739-20
P10066
AC-35718
(-)-cotinine 100 microg/ml in acetonitrile
(5~{s})-1-methyl-5-pyridin-3-yl-pyrrolidin-2-one
u5h ,
nc01 - nicotine and cotinine in urine

Research Excerpts

Toxicity

nicotine was 100-fold more toxic than cotinine. Cotinine is 10-fold faster than nicotine at producing respiratory arrest. Short-term administration of cotinin to humans is safe, says study.

ExcerptReferenceRelevance
" The subject was not smoking and the adverse event was deemed to be not related to the patch therapy."( High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels.
Croghan, IT; Fredrickson, PA; Gomez-Dahl, L; Hurt, RD; Lauger, G; Lee, GM; Offord, KP; Wingender, L, 1995
)
0.29
" This study demonstrates that short-term administration of cotinine to humans at levels as high as 10 times that attained from cigarette smoking is safe with no observable acute or withdrawal effects from cotinine in this setting."( Safety of cotinine in humans: physiologic, subjective, and cognitive effects.
Bliss, R; Grillo, M; Hatsukami, DK; Oncken, C; Pentel, PR, 1997
)
0.3
"Although nicotine nasal spray causes substantial irritant side effects during the first few days of use, these adverse effects decrease significantly within the first week."( Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels.
Croghan, GA; Croghan, IT; Dale, LC; Gomez-Dahl, LC; Hurt, RD; Offord, KP, 1998
)
0.3
" Nicotine was 100-fold more toxic than cotinine and 10-fold more rapid than cotinine at producing respiratory arrest."( Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity.
Baziard-Mouysset, G; Belahsen, Y; Courriere, P; Dousset, JC; Riah, O; Stigliani, JL, 1999
)
0.3
" For this reason, epidemiological and mechanistic research on the toxic effects of asbestos and mineral fibres is still needed."( Genotoxic effects of asbestos in humans.
Barancoková, M; Collins, A; Dusinská, M; Harrington, V; Horská, A; Kazimírová, A; Kocan, A; Kyrtopoulos, S; Machata, M; Petrík, J; Ratcliffe, B; Staruchová, M; Volkovová, K; Wsólová, L, 2004
)
0.32
" Adverse events (AEs) during the treatment period were recorded."( Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.
Cohen, J; Cui, Q; Elston, D; McFarland, N; McIvor, A; Quan, C; Robinson, L; Smaill, F; Smieja, M; Thabane, L; Zeidler, J, 2012
)
0.38
" The purpose of this study was to determine the incidence and severity of nicotine-related adverse events in subjects with levels of cotinine, a metabolite of nicotine, that increased by >50% compared with baseline smoking in controlled clinical trials of NRT."( Symptoms of nicotine toxicity in subjects achieving high cotinine levels during nicotine replacement therapy.
Gustavsson, G; Kruse, E; Tonstad, S; Walmsley, JM; Westin, Å, 2014
)
0.4
" In addition to baseline, at least 1 subsequent plasma or salivary cotinine concentration was measured, and adverse events were recorded simultaneously."( Symptoms of nicotine toxicity in subjects achieving high cotinine levels during nicotine replacement therapy.
Gustavsson, G; Kruse, E; Tonstad, S; Walmsley, JM; Westin, Å, 2014
)
0.4
"Nicotine has adverse cellular and molecular effects on oral mucosa, bone, and teeth."( Efficacy of vitamins E and C for reversing the cytotoxic effects of nicotine and cotinine.
Jamshidi, M; Mansuri Torshizi, A; Rezaei Esfahrood, Z; Sotoudeh, S; Torshabi, M, 2017
)
0.46
"Chronic exposure to tobacco smoke leads to chronic low-grade systemic inflammation; however, little is known about the dose-dependent toxic effect of objective tobacco smoking on systemic inflammation."( Dose-Dependent Toxic Effect of Cotinine-Verified Tobacco Smoking on Systemic Inflammation in Apparently Healthy Men and Women: A Nationwide Population-Based Study.
Cho, AR; Choi, WJ; Lee, JW; Lee, YJ, 2019
)
0.51
" However, these studies almost focused on the individual smoking pattern rather than the toxic ingredients of tobacco smoke."( Comprehensive evaluation of serum cotinine on human health: Novel evidence for the systemic toxicity of tobacco smoke in the US general population.
Hu, Y; Hua, L; Lei, T; Li, M; Yang, J; Zhu, Z, 2023
)
0.91

Pharmacokinetics

The method was successfully applied to biological samples obtained from a pharmacokinetic study conducted in adult smokers to investigate heat effect on nicotine and cotinine serum levels after nicotine transdermal delivery system (TDS) application.

ExcerptReferenceRelevance
"Physiologically based pharmacokinetic (PBPK) models have been developed describing the disposition kinetics of nicotine and its major metabolite, cotinine, in man."( A physiologically based pharmacokinetic model for nicotine and cotinine in man.
Balter, NJ; Robinson, DE; Schwartz, SL, 1992
)
0.28
" The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271."( Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers.
Chan, KK; John, VA; Piraino, AJ; Ross, HD, 1991
)
0.28
" The plasma concentration-time profiles of nicotine and cotinine and the pharmacokinetic parameters cmax, tmax, AUC and the elimination half-life were determined under steady-state conditions."( Pharmacokinetics of nicotine after application of a 30 cm2 nicotine patch under steady-state conditions.
Caspary, S; Huber, T; Keller-Stanislawski, B; Merz, PG, 1991
)
0.28
" As the clearance and distribution values in saliva were directly proportional to the corresponding values in plasma, similar terminal half-life values were obtained in the two body fluids, 15."( The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.
Curvall, M; Elwin, CE; Enzell, CR; Kazemi-Vala, E; Warholm, C, 1990
)
0.28
" Clearance (Cl), volume of distribution (Vd), and the biological half-life (t1/2) were calculated both from the infusion study and by fitting a monoexponential model to the iv blood data of the rat."( Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat.
Bondesson, U; Gabrielsson, J, 1987
)
0.27
" The data were analyzed by computer fitting, and the derived pharmacokinetic parameters were compared to those observed after a single iv injection of nicotine and after a single-cigarette smoke exposure."( Pharmacokinetics of nicotine in rats after multiple-cigarette smoke exposure.
Adir, J; Rotenberg, KS, 1983
)
0.27
"This randomized, crossover study compared the nicotine and cotinine pharmacokinetic parameters and plasma concentration profiles of two different nicotine transdermal products: Nicoderm (Alza, Palo Alto, CA; and Marion Merrell Dow, Kansas City, MO) and Habitrol (Basel Pharmaceuticals, Summit, NJ)."( Comparison of the pharmacokinetics of two nicotine transdermal systems: nicoderm and habitrol.
Eller, M; Gorsline, J; Gupta, SK; Okerholm, RA; Rolf, CN; Wei, G, 1995
)
0.29
" The in vivo delivery rate and the pharmacokinetic properties of a recently developed transdermal nicotine system (TNS) was investigated in three separate studies."( Transdermal nicotine substitution: pharmacokinetics of nicotine and cotinine.
Bonn, R; Caspary, S; Keller-Stanislawski, B; Merz, PG; Rietbrock, N; Wolff, M, 1993
)
0.29
"This study examined the effect of gender and body weight on the pharmacokinetic properties of the Nicotine Transdermal System (NTS) (Nicoderm)."( Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men.
Gorsline, J; Prather, RD; Rolf, CN; Tu, TG, 1993
)
0.29
" Time to reach peak concentration (tmax), half-life (t1/2), relative degree of fluctuation (DF) in steady-state plasma nicotine and cotinine concentrations, and renal cotinine clearance were similar for all three dosages, indicating linear pharmacokinetics and no change in nicotine metabolism with increasing dose."( Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System).
Dye, D; Gorsline, J; Gupta, SK; Rolf, CN, 1993
)
0.29
" After a single application, mean Cmax and tmax for plasma nicotine were 12."( Single- and multiple-dose pharmacokinetics of Nicoderm (Nicotine Transdermal System).
Coen, P; Gorsline, J; Gupta, SK; Okerholm, RA; Prather, RD, 1993
)
0.29
" Pharmacokinetic comparisons showed that nicotine Cmax, area under the curve (AUC)inf, and Cavg for the NTS were lower than corresponding values for controlled smoking; Cmax and Cavg values were approximately half those of smoking."( Comparison of the nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) and half-hourly cigarette smoking.
Causey, D; Gorsline, J; Gupta, SK; Hwang, SS; Rolf, CN, 1995
)
0.29
" Area under the concentration-time curves were calculated by the trapezoidal method, and the terminal elimination half-life was derived by extrapolation of the log-linear terminal phase."( Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis.
Evans, BK; Feyerabend, C; Fuller, GS; Green, JT; Newcombe, RG; Rhodes, J; Russell, MA; Sandborn, WJ; Thomas, GA, 1997
)
0.3
" This is the first evidence of pharmacokinetic predisposition to environmental tobacco smoke as an etiological factor in pediatric asthma."( Pharmacokinetic predisposition to nicotine from environmental tobacco smoke: a risk factor for pediatric asthma.
Eliopoulos, C; Greenwald, M; Klein, J; Knight, JM; Koren, G, 1998
)
0.3
" We have previously developed a topical enema combining nicotine with a polyacrylic carbomer; pharmacokinetic parameters were similar in healthy volunteers and patients with active ulcerative colitis."( Nicotine carbomer enemas--pharmacokinetics of a revised formulation.
Evans, BK; Feyerabend, C; Green, JT; Rhodes, J; Russell, MA; Sandborn, WJ; Thomas, GA, 1998
)
0.3
" The aim of this study was to develop an oral formulation of nicotine which would be slowly released in the colon over 6 h, and to examine its pharmacokinetic profile in 12 healthy volunteers, with measurements of serum nicotine and cotinine, its principal metabolite."( An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics.
Evans, BK; Feyerabend, C; Green, JT; Ranshaw, C; Rhodes, J; Russell, MA; Thomas, GA, 1999
)
0.3
" High concentrations of topical nicotine in the colon are achieved with relatively low systemic bioavailablity-reflected by the Cmax and AUC values for nicotine."( An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics.
Evans, BK; Feyerabend, C; Green, JT; Ranshaw, C; Rhodes, J; Russell, MA; Thomas, GA, 1999
)
0.3
" In addition, the feasibility of this assay method for pharmacokinetic studies of nicotine and cotinine after intravenous (i."( Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats.
Chung, BC; Chung, SJ; Jung, BH; Lee, MH; Shim, CK, 1999
)
0.3
" Drug disposition and pharmacodynamic responsiveness to nicotine may change with age, and conclusions founded on data from studies of younger populations may not apply to elderly populations."( Pharmacokinetics of nicotine in healthy elderly people.
Hansson, A; Lunell, E; Molander, L, 2001
)
0.31
" The data suggest that pregnant women who cannot quit heavy smoking in the second trimester form a selective group with pharmacokinetic predisposition to a high rate of nicotine metabolism."( Heavily smoking women who cannot quit in pregnancy: evidence of pharmacokinetic predisposition.
Hackman, R; Kapur, B; Klein, J; Koren, G; Selby, P, 2001
)
0.31
" Factorial analysis of variance (ANOVA) was used to evaluate the effects of smoking and gender on pharmacokinetic parameters."( Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender.
Berkel, HJ; Bocchini, JA; Manno, JE; Parish, RC; Simar, MR; Stewart, JJ; Syed, A; Wilson, JT, 2001
)
0.31
" Mucociliary clearance rates in terms of retention ratio after 1 hour and radioactivity half-life for each lung was lowest in the water-pipe smokers compared to others."( [The effects of water-pipe, cigarette and passive smoking on mucociliary clearance].
Aydin, A; Ceylan, E; Durak, H; Eminoğlu, O; Güven, H; Köseoğlu, N; Uçan, ES, 2006
)
0.33
" In addition, we found that administration of methoxsalen significantly increased the plasma half-life of nicotine (approximately doubled) and increased its area under the curve compared with saline treatment."( Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice.
Damaj, MI; Martin, BR; Sellers, EM; Siu, EC; Tyndale, RF, 2007
)
0.34
" However, other compounds metabolized by CYP2A6, as well as other drugs excreted via renal clearance mechanisms similar to those of nicotine, may be susceptible to significant pharmacokinetic grapefruit juice interactions."( Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.
Benowitz, NL; Hukkanen, J; Jacob, P, 2006
)
0.33
" A mechanistic population pharmacokinetic model was fitted to all data simultaneously."( Population pharmacokinetics of nicotine and its metabolites I. Model development.
Benowitz, NL; Dempsey, DA; Levi, M; Sheiner, LB, 2007
)
0.34
" COT and 3HC saliva concentrations in smokers were simulated utilizing a mechanistic population pharmacokinetic model of NIC metabolism that was adapted from the one described in a companion paper."( Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.
Benowitz, NL; Dempsey, DA; Levi, M; Sheiner, LB, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" We conducted a whole-genome linkage analysis to search for candidate regions influencing quantitative variation in cotinine pharmacokinetics in a large-scale pharmacokinetic study with 61 families containing 224 healthy adult participants."( Genome-wide linkage of cotinine pharmacokinetics suggests candidate regions on chromosomes 9 and 11.
Andrews, JA; Benowitz, N; Bergen, AW; He, Y; Hops, H; Lessov-Schlaggar, CN; Swan, GE; Tildesley, E; Webster, C, 2009
)
0.35
" Here, it is demonstrated for the first time that the pharmacokinetic and hemodynamic effects of a nicotine patch are significantly different between smokers and nonsmokers."( Effects of smoking on the pharmacokinetics and pharmacodynamics of a nicotine patch.
Baek, IH; Choi, JE; Kang, W; Kwon, KI; Seo, JW; Yun, HY, 2008
)
0.35
" For both compounds, a substantially longer plasma half-life and a greater area under the concentration-time curve were observed for the Cyp2a5-null mice, compared with wild-type mice."( Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model.
Ding, X; Humphreys, WG; Kluetzman, K; Shu, YZ; Xie, F; Zhou, X; Zhuo, X, 2010
)
0.36
"The present study defined a simplified physiologically based pharmacokinetic (PBPK) model for nicotine and its primary metabolite cotinine in humans, based on metabolic parameters determined in vitro using relevant liver microsomes, coefficients derived in silico, physiological parameters derived from the literature, and an established rat PBPK model."( Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.
Horiuchi, K; Kitajima, M; Murayama, N; Nagano, T; Shimizu, M; Shono, F; Takano, R; Yamazaki, H, 2010
)
0.36
" For pharmacokinetic characterization of nicotine and cotinine (a major and pharmacologically less active metabolite of nicotine), a rapid ultra-performance liquid chromatography/electrospray ionization-mass spectrometry (UPLC/ESI-MS) method was developed that requires only a small amount of sample and simple pretreatment."( Pharmacokinetic study of nicotine and its metabolite cotinine to clarify possible association between smoking and voiding dysfunction in rats using UPLC/ESI-MS.
Onoue, S; Seto, Y; Yamada, S; Yamamoto, N, 2011
)
0.37
" This study examined the effects of menthol on the pharmacokinetic (PK) profiles of bupropion and its principal metabolites, hydroxybupropion, threohydrobupropion, and erythrohydrobupropion among Black smokers."( Effects of menthol on the pharmacokinetics of bupropion among Black smokers.
Ahluwalia, JS; Benowitz, NL; Bronars, CA; Cox, LS; Faseru, B; Mayo, MS; Okuyemi, KS; Opole, I; Reed, GA; Whembolua, GL, 2012
)
0.38
" No differences were found by menthol smoking status in the Cmax and area under the plasma concentration versus time curve (AUC) of bupropion and its metabolites in the smoking or nonsmoking phases."( Effects of menthol on the pharmacokinetics of bupropion among Black smokers.
Ahluwalia, JS; Benowitz, NL; Bronars, CA; Cox, LS; Faseru, B; Mayo, MS; Okuyemi, KS; Opole, I; Reed, GA; Whembolua, GL, 2012
)
0.38
" If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown."( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012
)
0.38
"A dose-response effect was observed for all pharmacodynamic parameters tested."( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012
)
0.38
"Permeability-limited two-subcompartment and flow-limited, well-stirred tank tissue compartment models are routinely used in physiologically-based pharmacokinetic modeling."( Use of partition coefficients in flow-limited physiologically-based pharmacokinetic modeling.
Beard, DA; Thompson, MD; Wu, F, 2012
)
0.38
" A pharmacodynamic model relating nicotine levels to increases in heart rate as a proxy for the pharmacological effects of nicotine accurately described the nicotine related changes in heart rate and the development and decay of tolerance to nicotine."( A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans.
Gunawan, R; Hinderliter, PM; Housand, CJ; Smith, JN; Teeguarden, JG; Timchalk, CA, 2013
)
0.39
"Administration of intra peritoneal (ip) methoxsalen significantly increased nicotine's Cmax, prolonged the plasma half-life (fourfold decrease) of nicotine, and increased its area under the curve (AUC) compared with ip vehicle treatment."( Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
Alsharari, SD; Damaj, MI; Siu, EC; Tyndale, RF, 2014
)
0.4
"Smokers have a greater relative benefit of clopidogrel therapy compared with nonsmokers, likely attributed to its enhanced pharmacodynamic (PD) effects."( Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; Darlington, A; Degroat, C; Desai, B; Ferrante, E; Ferreiro, J; Franchi, F; Guzman, LA; Muniz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2014
)
0.4
" However, age-related pharmacokinetic differences may confound the interpretation of these findings."( Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.
Craig, EL; Cui, JZ; Miksys, S; Novalen, M; Tyndale, RF; Zhao, B, 2014
)
0.4
" In order to facilitate pharmacological and toxicological studies on COT for its pro-cognitive activities, we conducted a pharmacokinetic (PK) study of COT in rats, providing important oral and intravenously (iv) PK information."( Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.
Bartlett, MG; Beck, WD; Callahan, PM; Li, P; Terry, AV, 2015
)
0.42
" A non-compartmental analysis (cotinine, acetaldehyde) and Widmark equation (ethanol) were used for pharmacokinetic parameters calculation."( Influence of tobacco smoke exposure on pharmacokinetics of ethyl alcohol in alcohol preferring and non-preferring rats.
Florek, E; Gomółka, E; Jawień, W; Kulza, M; Napierała, M; Piekoszewski, W; Teżyk, A, 2015
)
0.42
" Lower values of the studied pharmacokinetic parameters were observed in the alcohol preferring males compared to the non-alcohol preferring rats."( Influence of tobacco smoke exposure on pharmacokinetics of ethyl alcohol in alcohol preferring and non-preferring rats.
Florek, E; Gomółka, E; Jawień, W; Kulza, M; Napierała, M; Piekoszewski, W; Teżyk, A, 2015
)
0.42
" The method was successfully applied to biological samples obtained from a pharmacokinetic study conducted in adult smokers to investigate heat effect on nicotine and cotinine serum levels after nicotine transdermal delivery system (TDS) application."( A fully validated LC-MS/MS method for simultaneous determination of nicotine and its metabolite cotinine in human serum and its application to a pharmacokinetic study after using nicotine transdermal delivery systems with standard heat application in adul
Abdallah, IA; Hammell, DC; Hassan, HE; Stinchcomb, AL, 2016
)
0.43
"Physiologically based pharmacokinetic (PBPK) modeling was applied to investigate the effects of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans."( A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.
Saylor, K; Zhang, C, 2016
)
0.43
" The organic cation transporter OCT2 rs316019 significantly increased nicotine and COT Cmax (P=0."( Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.
Benowitz, NL; St Helen, G; Taghavi, T; Tyndale, RF, 2017
)
0.46
" The nicotine levels and circadian patterns resembled the pharmacokinetic pattern of human smokers."( Chronic intermittent nicotine delivery via lung alveolar region-targeted aerosol technology produces circadian pharmacokinetics in rats resembling human smokers.
Feldman, JL; Fung, D; Lee, ES; Liang, J; Liu, S; Louie, S; Mudgway, R; Pei, H; Shao, XM; Xie, XS; Zhang, J; Zhu, Y, 2018
)
0.48
" Plasma concentrations of nicotine and cotinine were measured, and pharmacokinetic parameters were estimated."( Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers.
Benowitz, NL; Dempsey, DA; Jacob, P; Liakoni, E; St Helen, G; Tyndale, RF, 2019
)
0.51
" A physiologically-based pharmacokinetic (PBPK) model was created to characterize the pharmacokinetic behaviors of nicotine and its metabolites, cotinine, trans-3'-hydroxycotinine (3'-OH cotinine), and trans-3'-hydroxycotinine glucuronide (3'-OH cotinine glucuronide) for both adult and adolescent squirrel monkeys."( Use of a physiologically-based pharmacokinetic model to explore the potential disparity in nicotine disposition between adult and adolescent nonhuman primates.
Bryant, M; Chemerynski, S; Deng-Bryant, Y; Fisher, J; Gamboa da Costa, G; Goodwin, A; Jackson, K; Jacob, CC; Loukotková, L; Matazel, K; Naylor, J; Reissig, C; Yang, X, 2020
)
0.56
"Baseline plasma and urine biomarker data were available from two smoking cessation clinical trials and one nicotine pharmacokinetic study (total N = 768)."( Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies.
Addo, N; Ahluwalia, JS; Benowitz, NL; Chenoweth, MJ; Cox, LS; George, TP; Giratallah, HK; Lerman, C; Tyndale, RF, 2021
)
0.62
" NMR is renowned for its straightforward data interpretation and quantitative properties, making it attractive for pharmacokinetic applications, where drug metabolism pathways, concentrations, and kinetics need to be evaluated."( Developing Analytical Applications for Parahydrogen Hyperpolarization: Urinary Elimination Pharmacokinetics of Nicotine.
Ausmees, K; Reile, I; Reimets, N; Vija, S, 2021
)
0.62

Compound-Compound Interactions

Zinc sulfate is a recently introduced urinary adulterant, which causes false-negative results with immunoassays used for screening drugs of abuse in urine. Whether zinc sulfate also could invalidate urine cotinine assay has never been studied.

ExcerptReferenceRelevance
"To determine the efficacy of a 22-mg nicotine patch combined with the National Cancer Institute program for physician advice and nurse follow-up in providing withdrawal symptom relief, 1-year smoking cessation outcome, and percentage of nicotine replacement."( Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement.
Caldwell, CC; Dale, LC; Fredrickson, PA; Hurt, RD; Lauger, GG; Lee, GA; Lundberg, TG; Marŭsić, Z; Neese, LW; Offord, KP, 1994
)
0.29
"Clinically significant smoking cessation can be achieved using nicotine patch therapy combined with physician intervention, nurse counseling, follow-up, and relapse prevention."( Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement.
Caldwell, CC; Dale, LC; Fredrickson, PA; Hurt, RD; Lauger, GG; Lee, GA; Lundberg, TG; Marŭsić, Z; Neese, LW; Offord, KP, 1994
)
0.29
"Zinc sulfate is a recently introduced urinary adulterant, which causes false-negative results with immunoassays used for screening drugs of abuse in urine but whether zinc sulfate also could invalidate urine cotinine assay using immunoassay or liquid chromatography combined with mass spectrometry has never been studied."( Zinc Sulfate, a Recently Introduced Urinary Adulterant Can Invalidate Urine Cotinine Test Using Immunoassay but Has Less Effect on Liquid Chromatography Combined With Tandem Mass Spectrometry-Based Test.
Dasgupta, A; Dixon, RB, 2015
)
0.42
"Four urine pools containing none detected to high levels of cotinine were analyzed using DRI cotinine immunoassay on the Olympus 640 analyzer as well as using liquid chromatography combined with tandem mass spectrometry."( Zinc Sulfate, a Recently Introduced Urinary Adulterant Can Invalidate Urine Cotinine Test Using Immunoassay but Has Less Effect on Liquid Chromatography Combined With Tandem Mass Spectrometry-Based Test.
Dasgupta, A; Dixon, RB, 2015
)
0.42
"4% when analyzed using liquid chromatography combined with mass spectrometry."( Zinc Sulfate, a Recently Introduced Urinary Adulterant Can Invalidate Urine Cotinine Test Using Immunoassay but Has Less Effect on Liquid Chromatography Combined With Tandem Mass Spectrometry-Based Test.
Dasgupta, A; Dixon, RB, 2015
)
0.42
"Zinc sulfate caused false-negative cotinine result when DRI immunoassay was used and also had small to moderate impact on liquid chromatography combined with tandem mass spectrometry-based assay for urine cotinine."( Zinc Sulfate, a Recently Introduced Urinary Adulterant Can Invalidate Urine Cotinine Test Using Immunoassay but Has Less Effect on Liquid Chromatography Combined With Tandem Mass Spectrometry-Based Test.
Dasgupta, A; Dixon, RB, 2015
)
0.42
"To develop a method for the determination of nicotine and cotinine in urine samples by dispersive liquid-liquid microextraction (DLLME) combined with gas chromatography-mass spectrometry (DLLME-GC/MS)."( [Determination of Nicotine and Cotinine in Urine by Dispersive Liquid-Liquid Microextraction Combined with Gas Chromatography-Mass Spectrometry].
Lei, L; Li, Y; Zheng, QY; Zhu, J; Zou, XL, 2016
)
0.43
" This study compared the effectiveness in black NDS of smoking cessation counseling alone or in combination with the participant's choice of nicotine replacement therapy."( Counseling alone or in combination with nicotine replacement therapy for treatment of black non-daily smokers: a randomized trial.
Ahluwalia, JS; Cox, LS; Ellerbeck, EF; Mayo, MS; Nollen, NL, 2020
)
0.56
"Twelve weeks of in-person and telephone smoking cessation counseling in combination with nicotine replacement therapy (NRT; C + NRT) or counseling alone (C)."( Counseling alone or in combination with nicotine replacement therapy for treatment of black non-daily smokers: a randomized trial.
Ahluwalia, JS; Cox, LS; Ellerbeck, EF; Mayo, MS; Nollen, NL, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The analytical methods were set up to study the pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administrations of different doses of transdermal nicotine systems."( High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine.
Dubois, JP; Parisot, C; Sandrenan, N; Sioufi, A, 1989
)
0.28
" Previously reported methodology for determining nicotine bioavailability has been improved by using stable isotope-labeled nicotine administered intravenously."( Recent studies of nicotine metabolism in humans.
Benowitz, NL; Jacob, P; Shulgin, AT, 1988
)
0.27
" This study also validates a recently proposed method for estimating absolute bioavailability of a drug using drug and metabolite pharmacokinetic data, and presents novel data on plasma levels of the metabolite trans-3'-hydroxycotinine in people."( Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
Benowitz, NL; Jacob, P; Zevin, S, 1997
)
0.3
"Oral nicotine administration failed to consistently increase GG muscle activation which may be a problem of local bioavailability of nicotine in the muscle."( The influence of a transmucosal cholinergic agonist on pharyngeal muscle activity.
Chajek-Shaul, T; Edwards, JK; Slamowitz, DI; White, DP, 2000
)
0.31
" These results suggest a time and biphasic dose effect of nicotine treatment on endothelium-dependent responses that may be related to bioavailability of NO."( Time and dose effect of transdermal nicotine on endothelial function.
Bonde, S; Boston, US; Clouse, WD; Hurt, RD; Miller, VM; Rud, KS; Severson, SR; Tonnessen, BH, 2000
)
0.31
" Smoking affected infant's height during breastfeeding, attributed to an eventual impaired bioavailability of essential nutrients."( Maternal smoking effects on infant growth.
Berlanga, Mdel R; Garcia, C; Hernandez, J; Salazar, G, 2002
)
0.31
" Potent and specific inhibitors of the CYP2A6 enzyme can be used in the future to increase nicotine bioavailability and thus make oral nicotine administration feasible in smoking cessation therapy."( Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Juvonen, RO; Poso, A; Rahnasto, M; Raunio, H; Wittekindt, C, 2005
)
0.33
"991 microg/ml), a nicotine absorption rate equivalent to smoking 10 cigarettes/day (95% CI = 7-13 cigarettes/day)."( Waterpipe smoking and nicotine exposure: a review of the current evidence.
Job, J; Montgomery, S; Neergaard, J; Singh, P, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Our results suggest that inhibiting nicotine metabolism can be used to dramatically enhance nicotine's bioavailability and its resulting pharmacology, which further supports this inhibitory approach for clinical development of an oral nicotine replacement therapy."( Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
Alsharari, SD; Damaj, MI; Siu, EC; Tyndale, RF, 2014
)
0.4
" The results suggested fast absorption, slow elimination and high bioavailability of COT in rats."( Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.
Bartlett, MG; Beck, WD; Callahan, PM; Li, P; Terry, AV, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Metabolizing enzyme to produce cotinine from nicotine was saturated after multiple oral dosing for 4 weeks in a low dose (1 mg/kg/day) We explored the dose-response relationship of this association, using smoking history and serum cotinin and thiocyanate concentrations as measures of tobacco exposure.

ExcerptRelevanceReference
"In 6-day pregnant New Zealand White rabbits dosed intravenously with 3H-nicotine, the 3H-activity in the uterine fluid was approximately 5 to 11 times greater than that in the plasma at the corresponding times; 3H-nicotine itself accounted for most of this radioactivity."( Accumulation of nicotine in the uterine fluid of the six-day pregnant rabbit.
Dames, NM; Fabro, S; McLachlan, JA; Sieber, SM, 1976
)
0.26
" The individual models were tested through simulations of published studies of nicotine and cotinine infusions in man using similar dosing protocols to those reported."( A physiologically based pharmacokinetic model for nicotine and cotinine in man.
Balter, NJ; Robinson, DE; Schwartz, SL, 1992
)
0.28
" Results for Experiment 2 showed very little effect of acute nicotine dosing on the overall responding and varying effects on the responding during the interval following unavoidable point losses."( Human avoidance responding with added point loss: effects of tobacco and abstinence.
Bennett, RH; Cherek, DR, 1992
)
0.28
" Mice were dosed three times per day on gestational days 6-15."( Alcohol and smokeless tobacco effects on the CD-1 mouse fetus.
Dean, J; Fernandez, M; Mullet, D; Paulson, JO; Paulson, RB; Shanfeld, J,
)
0.13
" The pattern of metabolites after iv dosing suggests that there is systemic reduction of NNO, although the magnitude of that reduction is small, with less than 3% reduced to nicotine."( Disposition kinetics and metabolism of nicotine-1'-N-oxide in rabbits.
Benowitz, NL; Duan, MJ; Jacob, P; Savanapridi, C; Yu, L,
)
0.13
" cis-3'-Hydroxycotinine was detected as an S(-)-nicotine metabolite in the urine of smokers as well as in the urine of rats and hamsters dosed with nicotine."( Identification of cis-3'-hydroxycotinine as a urinary nicotine metabolite.
Rustemeier, K; Schepers, G; Voncken, P, 1990
)
0.28
" Convex dose-response relationships were found between the amount smoked and ABP hemoglobin adduct levels or urinary mutagenicity."( Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers.
Bartsch, H; Caporaso, N; Coda, M; Kadlubar, F; Malaveille, C; Skipper, P; Talaska, G; Tannenbaum, SR; Vineis, P, 1990
)
0.28
" Our results suggest the dose-response curves differ for nicotine gum's reinforcing, withdrawal-suppression and self-reported effects."( Effect of dose on nicotine's reinforcing, withdrawal-suppression and self-reported effects.
Fenwick, JW; Gust, SW; Hughes, JR; Keenan, RM, 1990
)
0.28
" The mean maternal plasma nicotine level for the low dosage (1 X) group was 99."( Effect of smokeless tobacco on the development of the CD-1 mouse fetus.
Paulson, J; Paulson, R; Price, T; Sachs, L; Shanfeld, J, 1989
)
0.28
" Non-smokers absorb measurable amounts of nicotine from breathing other people's smoke, and dose-response relationships are apparent."( Application of biochemical intake markers to passive smoking measurement and risk estimation.
Jarvis, MJ, 1989
)
0.28
" A novel method using gas chromatography-mass spectrometry (GC-MS) has been used to monitor the presence of this adduct in smokers and control subjects, and dose-response relationships were investigated between HOEtVal in haemoglobin, number of cigarettes smoked per day and plasma cotinine levels."( 2-Hydroxyethylation of haemoglobin in man.
Bailey, E; Brooks, AG; Farmer, PB; Passingham, BJ; Yates, DW, 1988
)
0.27
" Finally, the confirmation that dose-response relationships exist between cotinine concentrations and self-reported passive smoking validates questionnaire measures of the degree of environmental smoke exposure."( Uptake of environmental tobacco smoke.
Jarvis, MJ, 1987
)
0.27
" These findings are consistent with a causal relationship between passive exposure to tobacco smoke and birth weight and suggest that the dose-response relationship may not be linear."( Second-trimester serum cotinine levels in nonsmokers in relation to birth weight.
Haddow, JE; Knight, GJ; McCarthy, JE; Palomaki, GE, 1988
)
0.27
" Monitoring of smoke intakes could supplement epidemiological approaches and provide earlier evidence of whether changing cigarette designs lead to any significant dosage reduction that could affect the risk of disease."( Reduction of tar, nicotine and carbon monoxide intake in low tar smokers.
Feyerabend, C; Jarvis, MJ; Russell, MA; Saloojee, Y, 1986
)
0.27
" A dose-response curve was obtained for the place conditioning effect of nicotine as measured by its ability to alter baseline preferences calculated from control rats."( Further studies on nicotine-induced conditioned place preference in the rat.
Fudala, PJ; Iwamoto, ET, 1986
)
0.27
" The mean absorption time after oral dosing ranged between 1 and 3 h, the peak concentration was reached within 45 min and the mean elimination half-lives were 12."( Kinetics of cotinine after oral and intravenous administration to man.
Daenens, P; De Schepper, PJ; Van Hecken, A; Van Rossum, JM, 1987
)
0.27
" Compared to the control (untreated) group of animals, the 24-hour hydroxyproline output (relative to creatinine) was lower for all dilutions of smoke and showed a negative dose-response relationship."( Preliminary studies of urinary hydroxyproline levels in rodents and in smokers.
Read, GA; Thornton, RE, 1985
)
0.27
" The slope of the dose-response curve was quite shallow (6-8% change in binding per doubling dose), resulting in between-assay CVs of 15 to 20%."( Improved 125I radioimmunoassay for cotinine by selective removal of bridge antibodies.
Haddow, JE; Holman, MS; Knight, GJ; Wylie, P, 1985
)
0.27
"Four weeks of 22- or 44-mg transdermal nicotine therapy followed by 4 weeks of dosage reduction (2 weeks of 22 mg followed by 2 weeks of 11 mg)."( Varying nicotine patch dose and type of smoking cessation counseling.
Baker, TB; Croghan, IT; Fiore, MC; Hays, JT; Hurt, RD; Jorenby, DE; Lewis, SF; Offord, KP; Smith, SS, 1995
)
0.29
" At week 4, the dosage of those initially assigned to 44 mg/d was reduced to 22 mg/d."( High-dose nicotine patch therapy. Percentage of replacement and smoking cessation.
Croghan, IT; Dale, LC; Hurt, RD; Lawson, GM; Offord, KP; Schroeder, DR, 1995
)
0.29
" A dose-response relationship was observed with higher patch doses, which produced a higher percentage of cotinine replacement and better withdrawal symptom relief."( High-dose nicotine patch therapy. Percentage of replacement and smoking cessation.
Croghan, IT; Dale, LC; Hurt, RD; Lawson, GM; Offord, KP; Schroeder, DR, 1995
)
0.29
" By regression analysis, after adjustment for ethnicity, there was a significant dose-response relationship between cotinine and the number of cigarettes smoked per day by the mother, both in the children (partial r2 = ."( Biomarkers of environmental tobacco smoke in preschool children and their mothers.
Cooper, TB; Crawford, FG; Mayer, J; Ottman, R; Perera, FP; Santella, RM; Simon-Cereijido, G; Tang, D; Tsai, WY; Wang, M, 1994
)
0.29
" This increase of infarct size exhibited a dose-response relation."( Exposure to environmental tobacco smoke increases myocardial infarct size in rats.
Glantz, SA; Parmley, WW; Sievers, RE; Sun, YP; Wolfe, CL; Zhu, BQ, 1994
)
0.29
" A dose-response relationship was also more consistently apparent."( Replacing creatinine measurements with specific gravity values to adjust urine cotinine concentrations.
Chilmonczyk, BA; Haddow, JE; Knight, GJ; Neveux, LM; Palomaki, GE, 1994
)
0.29
" Adduct analyses with varying amounts of DNA from lungs of mid- and high-exposure animals clearly indicate that the dose-response for DNA adduct formation is nonlinear."( Ninety-day inhalation study in rats, using aged and diluted sidestream smoke from a reference cigarette: DNA adducts and alveolar macrophage cytogenetics.
Brown, BG; Coggins, CR; Doolittle, DJ; Hayes, AW; Lee, CK; Reed, EA, 1993
)
0.29
" Findings from a second study also reflect the linear dose relationship for this Nicotine Transdermal System within the 7 to 21 mg/day dosage range."( Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System).
Dye, D; Gorsline, J; Gupta, SK; Rolf, CN, 1993
)
0.29
" The effects of nicotine in people are influenced by the rate and route of dosing and by the development of tolerance."( Pharmacology of nicotine: addiction and therapeutics.
Benowitz, NL, 1996
)
0.29
" To define better the optimal dosing of nicotine patch therapy, we undertook an open-label study to determine the safety and tolerability of 44 mg/day dose for smoking cessation in subjects smoking > or = 20 cigarettes per day."( High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels.
Croghan, IT; Fredrickson, PA; Gomez-Dahl, L; Hurt, RD; Lauger, G; Lee, GM; Offord, KP; Wingender, L, 1995
)
0.29
" There was a dose-response relationship between the number of cigarettes smoked daily and the risk of active pulmonary tuberculosis."( Cigarette smoking as a risk factor for tuberculosis in young adults: a case-control study.
Alcaide, J; Altet, MN; Domínguez, A; Folguera, L; Pardell, H; Parrón, I; Plans, P; Salleras, L; Saltó, E, 1996
)
0.29
"The data studied show that cigarette smoking is a risk factor for pulmonary tuberculosis in young people, with a dose-response relationship with the number of cigarettes consumed daily."( Cigarette smoking as a risk factor for tuberculosis in young adults: a case-control study.
Alcaide, J; Altet, MN; Domínguez, A; Folguera, L; Pardell, H; Parrón, I; Plans, P; Salleras, L; Saltó, E, 1996
)
0.29
" The dosage was gradually decreased from week 12 to discontinuation at week 39."( The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain.
Iversen, E; Jakobsen, HB; Jørgensen, S; Mikkelsen, KL; Nørregaard, J; Søeberg, B; Sørensen, T; Tønnesen, P, 1996
)
0.29
"Transdermal nicotine administered at the highest tolerated dosage (< or = 22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis."( Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial.
Batts, KP; Croghan, IT; Dale, LC; Hurt, RD; Lawson, GM; Offord, KP; Petersen, BT; Sandborn, WJ; Schroeder, DR; Tremaine, WJ, 1997
)
0.3
" This study aimed primarily to assess sources of individual variability in nicotine and metabolite plasma levels from these dosing systems and from cigarette smoking."( Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
Benowitz, NL; Jacob, P; Zevin, S, 1997
)
0.3
" To compensate for individual differences in clearance, individualization of nicotine dosing based on therapeutic drug monitoring with comparison to nicotine or continine levels during cigarette smoking prior to treatment may be necessary to optimize nicotine therapy."( Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
Benowitz, NL; Jacob, P; Zevin, S, 1997
)
0.3
" Allowance for this transforms the observed linear dose-response relationship into one consistent with the expected quadratic relationship."( The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer.
Law, MR; Morris, JK; Wald, NJ; Watt, HC, 1997
)
0.3
"Adult smokers were recruited to use the nicotine nasal spray for smoking cessation at a dosage of 1 to 2 mg/h."( Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels.
Croghan, GA; Croghan, IT; Dale, LC; Gomez-Dahl, LC; Hurt, RD; Offord, KP, 1998
)
0.3
" The EACO levels were related to the number of cigarettes smoked per day in a dose-response fashion."( [Exposure to tobacco smoke in a Japanese urban population. An analysis using biochemical markers of smoking].
Baba, S; Konishi, M; Mannami, T; Terao, A, 1998
)
0.3
" First, with the higher nicotine and cotinine levels observed with heavier smoking, it is inherent that one size does not fit all, and there is a need to consider more individualization of dosage for nicotine patch therapy."( Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy.
Croghan, IT; Dale, LC; Hurt, RD; Jiang, NS; Lawson, GM; Offord, KP; Schroeder, DR, 1998
)
0.3
" (-)-Nicotine exhibited a bell-shaped dose-response relationship, and showed attenuation of response at the highest dose (5."( Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain--an in vivo microdialysis study.
Imoto, M; Ohno, T; Saito, K; Tani, Y, 1998
)
0.3
" A dose-response relationship between attendance at group sessions and abstinence status was shown at posttreatment and 6-month follow-up intervals."( Preliminary investigation of a culturally specific smoking cessation intervention for Hispanic smokers.
Javier, RA; Nevid, JS,
)
0.13
" dose of nicotine effected a transient, lung-specific induction of cytochrome P-450 (CYP) 1A1 in the rat, a dose-response study and assessment of the lung specificity of the induction was limited by toxicity of the acute parenteral nicotine exposure."( Dose-dependent up-regulation of rat pulmonary, renal, and hepatic cytochrome P-450 (CYP) 1A expression by nicotine feeding.
Fisher, H; Fung, J; Halladay, AK; Iba, MM; Pak, YW; Sekowski, A; Thomas, PE; Wagner, GC, 1999
)
0.3
"04), suggesting a dose-response relationship."( Maternal smoking and fetal erythropoietin levels.
Clinch, JJ; Fleming, N; Gruslin, A; Manchanda, R; Perkins, SL, 2000
)
0.31
"When administered acutely to nonsmokers, nicotine's effects on performance are inconsistent, perhaps because of suboptimal dosing or initial dysphoria that could interfere with performance."( Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers.
Heishman, SJ; Henningfield, JE, 2000
)
0.31
" In addition, a dose-response relationship was observed between levels of tobacco exposure and serum ascorbic acid levels."( Environmental tobacco smoke and serum vitamin C levels in children.
Strauss, RS, 2001
)
0.31
" The results with Chinese-Americans may have implications for dosing with nicotine medications to aid smoking cessation in Chinese- American smokers and perhaps in other Asian smokers."( Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans.
Benowitz, NL; Herrera, B; Jacob, P; Pérez-Stable, EJ, 2002
)
0.31
"This was a prospective study of the effects of maternal smoking during pregnancy on newborn neurobehavior, including dose-response relationships using self-report and a bioassay of nicotine exposure."( Smoking during pregnancy and newborn neurobehavior.
LaGasse, LL; Law, KL; Lester, BM; Liu, J; Niaura, R; Stroud, LR, 2003
)
0.32
" Dose-response relationships with NNNS scores were computed for maternal salivary cotinine and maternal report of number of cigarettes per day during pregnancy."( Smoking during pregnancy and newborn neurobehavior.
LaGasse, LL; Law, KL; Lester, BM; Liu, J; Niaura, R; Stroud, LR, 2003
)
0.32
" Dose-response relationships could indicate neonatal withdrawal from nicotine."( Smoking during pregnancy and newborn neurobehavior.
LaGasse, LL; Law, KL; Lester, BM; Liu, J; Niaura, R; Stroud, LR, 2003
)
0.32
" There were positive and significant dose-response relationships between measures of cigarette smoking (cigarettes per day, pack-years, and serum cotinine levels) and elevated levels of novel risk factors."( Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States.
Bazzano, LA; He, J; Muntner, P; Vupputuri, S; Whelton, PK, 2003
)
0.32
" The shape of the dose-response curve and a comparison with previous data suggest that cigarette smoke is only a comparatively weak mouse lung carcinogen."( Lung tumor response in strain a mice exposed to tobacco smoke: some dose-effect relationships.
Espiritu, I; Pinkerton, KE; Suffia, M; Uyeminami, D; Witschi, H, 2004
)
0.32
" Dosing repeatedly with The Straw led to greater nicotine levels that continued to increase with additional dosing."( Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product.
D'Orlando, KJ; Fox, BS, 2004
)
0.32
" The clinician prescribing a dosage for a patient has to take all these parameters into account to make an accurate choice."( [Usefulness of biological markers in evaluation of smoking].
Asnafi-Farhang, S; Diviné, C; Lagrue, G; Larramendy, C, 2004
)
0.32
" For all mice, nicotine consumption and serum cotinine levels increased in a dose-dependent manner, and the volume of nicotine intake (ml), percent nicotine intake, and nicotine dosage (mg/kg) on the last day of the experiment were positively correlated with cotinine levels."( Sex differences in voluntary oral nicotine consumption by adolescent mice: a dose-response experiment.
Kamens, HM; Klein, LC; Stine, MM; Vandenbergh, DJ; Whetzel, CA, 2004
)
0.32
" We explored the dose-response relationship of this association, using smoking history and serum cotinine and thiocyanate concentrations as measures of tobacco exposure."( Smoking history and serum cotinine and thiocyanate concentrations as determinants of rheumatoid factor in non-rheumatoid subjects.
Aho, K; Aromaa, A; Heliövaara, M; Knekt, P; Korpilähde, T; Marniemi, J, 2004
)
0.32
"The results are not in line with the hypothesis of a dose-response relationship between smoking exposure and RF positivity."( Smoking history and serum cotinine and thiocyanate concentrations as determinants of rheumatoid factor in non-rheumatoid subjects.
Aho, K; Aromaa, A; Heliövaara, M; Knekt, P; Korpilähde, T; Marniemi, J, 2004
)
0.32
"We have studied the relationship between urinary cotinine and other tobacco markers to assess the relevance of urinary cotinine in the dosage of nicotine substitutes."( [Usefulness of biological markers in the evaluation of smoking at the first visit of a smoking cessation program].
Favreau, M; Ingrand, P; Meurice, JC; Mura, P; Underner, M, 2004
)
0.32
" It becomes useful if the CO level is between 15 and 34 ppm, as CO level in itself is insufficient to determine the dosage of nicotine substitutes."( [Usefulness of biological markers in the evaluation of smoking at the first visit of a smoking cessation program].
Favreau, M; Ingrand, P; Meurice, JC; Mura, P; Underner, M, 2004
)
0.32
" These results may have implications for dosing with nicotine medications to aid smoking cessation in Mexican smokers and suggest that whether the cigarette is labeled light or regular has no relationship to nicotine dose from smoking cigarettes."( Determinants of salivary cotinine levels among current smokers in Mexico.
Bautista, P; Benowitz, NL; Blackford, A; Campuzano, JC; Ceraso, M; Hernandez-Avila, M; Jaakkola, MS; Kuri Morales, P; Lazcano Ponce, E; Samet, JM, 2004
)
0.32
" There was no evidence of a dose-response relation."( Smoking and Helicobacter pylori infection in a sample of U.S. adults.
Cardenas, VM; Graham, DY, 2005
)
0.33
"Epidemiologic studies show a dose-response relationship between cigarettes per day and health outcomes such as heart and lung disease, and health outcomes are related to some biomarkers of tobacco exposure."( Relationships between cigarette consumption and biomarkers of tobacco toxin exposure.
Carmella, SG; Han, S; Hatsukami, DK; Hecht, SS; Joseph, AM; Le, CT; Murphy, SE; Zhang, Y, 2005
)
0.33
"Adolescents did not display the decreases in brain reward function observed in adults experiencing withdrawal, and displayed fewer somatic signs of nicotine withdrawal relative to adults regardless of the dosing procedure used."( Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction.
Bruijnzeel, AW; Goldberger, BA; Koob, GF; Markou, A; Merves, ML; O'Dell, LE; Parsons, LH; Richardson, HN; Smith, RT, 2006
)
0.33
" A nonsignificant dose-response association was seen between increasing daily exposure to ETS and reduction in birth weight."( The effect of environmental tobacco smoke during pregnancy on birth weight.
Hegaard, HK; Kjaergaard, H; Møller, LF; Ottesen, B; Wachmann, H, 2006
)
0.33
"In all countries, air nicotine concentrations increased with increasing questionnaire reported smoking in a dose-response fashion."( Comparison of parental reports of smoking and residential air nicotine concentrations in children.
Bellander, T; Brunekreef, B; Gehring, U; Giovannangelo, ME; Heinrich, J; Hoek, G; Leaderer, BP; Merkel, G; Nordling, E; Oldenwening, M, 2006
)
0.33
" However, in multivariate logistic regression, cotinine levels above the median were not associated with failed fertilization, failed implantation or spontaneous abortion, nor was there evidence of a dose-response relationship among cotinine quintiles."( Maternal exposure to second-hand tobacco smoke and pregnancy outcome among couples undergoing assisted reproduction.
Cramer, DW; Hauser, R; Meeker, JD; Missmer, SA, 2007
)
0.34
" Dose-proportional increases in maximum observed plasma concentrations and area under the plasma concentration-time curve from time zero to the end of the dosing interval values were observed between the 1-mg and 2-mg daily doses of varenicline."( Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
Burstein, AH; Clark, DJ; Faessel, HM; Gibbs, MA; Rohrbacher, K; Stolar, M, 2006
)
0.33
"We provide novel pharmacokinetic and metabolic data on nicotine after systemic dosing in relation to common CYP2A6 genotypes."( CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz, NL; Jacob, P; Lessov-Schlaggar, CN; Swan, GE; Tyndale, RF, 2006
)
0.33
" Cigarette smoking increased heart rate and decreased skin temperature, but the nicotine dose-response curve flattened at higher doses, with a maximal response being observed in cigarettes at a nicotine content level of about 8 mg."( Nicotine intake and dose response when smoking reduced-nicotine content cigarettes.
Benowitz, NL; Herrera, B; Jacob, P, 2006
)
0.33
" Individualized dosing of nicotine replacement therapy (NRT) may improve product efficacy, but a better understanding of the within-day and within-subject relationships between smoking, NRT use, nicotine and cotinine concentrations in blood, and cravings and withdrawal symptoms is needed to inform dosing algorithms."( Nicotine, cotinine, withdrawal, and craving patterns during smoking and nicotine nasal spray use: results from a pilot study with African American men.
Augustson, EM; Benowitz, NL; Mabry, PL; Malcolm, RJ; Moser, RP; Tooze, JA, 2007
)
0.34
"We dosed 36 nonsmokers with 100, 200, or 400 microg deuterium-labeled nicotine (simulating exposure to SHS) by mouth daily for 5 days and then measured plasma and urine cotinine and metabolites at various intervals over 24 hr."( Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure.
Benowitz, NL; Dains, KM; Dempsey, D; Herrera, B; Jacob, P; Yu, L, 2009
)
0.35
" Considering the biological plausibility and dose-response relationship between SHS and CVD, effective interventions that incorporate a comprehensive screening method of behavioral and biological measures of exposure coupled with efficacious treatment should elicit favorable change for at-risk populations."( Epidemiological evidence associating secondhand smoke exposure with cardiovascular disease.
Cairney, J; Faught, BE; Flouris, AD, 2009
)
0.35
" Metabolizing enzyme to produce cotinine from nicotine was saturated after multiple oral dosing for 4 weeks in a low dose (1 mg/kg/day), but within 1 week in the dose of 5 and 10 mg/kg/day."( Relations between toxicity and altered tissue distribution and urinary excretion of nicotine, cotinine, and hydroxycotinine after chronic oral administration of nicotine in rats.
Chung, BC; Hong, J; Jung, BH; Kim, KY; Lee, YJ, 2010
)
0.36
" We evaluated the dose-response effects of nicotine on locomotor activity, song production, food intake and body weight."( In vivo nicotine exposure in the zebra finch: a promising innovative animal model to use in neurodegenerative disorders related research.
Cappendijk, SL; Chalise, P; Halquist, MS; James, JR; Miller, GL; Pirvan, DF; Rodriguez, MI, 2010
)
0.36
" The discrepancy between cotinine levels in relation to disease risk comparing active versus passive smoking suggests a nonlinear tobacco smoke dose-response and/or that cotinine is not providing an accurate measure of exposure to the toxic constituents of secondhand tobacco smoke."( Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers.
Benowitz, N; Eisner, MD; Goniewicz, ML; Havel, C; Jacob, P; Koszowski, B; Lazcano-Ponce, E; Sobczak, A; Zielinska-Danch, W, 2010
)
0.36
" There was evidence of a dose-response effect across the cotinine group (P trend = ."( Objectively measured secondhand smoke exposure and mental health in children: evidence from the Scottish Health Survey.
Batty, GD; Dockray, S; Ford, T; Hamer, M; Stamatakis, E, 2011
)
0.37
"The dose-response between CPD and nicotine equivalents, and NNAL and PAH was flat for Black but positive for White smokers (Race × CPD interaction, all ps < ."( Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.
Benowitz, NL; Dains, KM; Dempsey, D; Jacob, P; Wilson, M, 2011
)
0.37
" This analytical method provides support for preclinical NIC pharmacokinetic and toxicological studies after controlled dosing protocols."( Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.
Fleckenstein, AE; Miller, EI; Nielsen, SM; Vieira-Brock, PL; Wilkins, DG, 2011
)
0.37
" Systolic blood pressure (SBP) increased in a linear fashion across a dosage of PM(2."( Prohypertensive effect of gestational personal exposure to fine particulate matter. Prospective cohort study in non-smoking and non-obese pregnant women.
Flak, E; Jacek, R; Jedrychowski, WA; Kaim, I; Majewska, R; Maugeri, U; Mroz, E; Perera, FP; Sowa, A; Spengler, J; Stigter, L, 2012
)
0.38
"This study sought to assess the presence of a dose-response effect of cigarette smoking and its impact on high on-treatment platelet reactivity (HPR) in patients with diabetes mellitus treated with clopidogrel."( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012
)
0.38
" If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown."( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012
)
0.38
"A dose-response effect was observed for all pharmacodynamic parameters tested."( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012
)
0.38
"Cigarette smoking is associated with a dose-response effect on clopidogrel-induced antiplatelet effects and lower rates of HPR in diabetes mellitus patients."( Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012
)
0.38
" One mechanism may be extinction, but the duration of the current dosing protocol may not be sufficient."( Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.
Ashare, RL; Blair, IA; Leone, F; Mesaros, AC; Strasser, AA; Tang, KZ, 2012
)
0.38
" Dose-response relationships between BMD and urinary cotinine levels were estimated using analysis of covariance in pre-menopausal females and postmenopausal females, respectively."( Dose-related effect of urinary cotinine levels on bone mineral density among Korean females.
Choi, SE; Kim, HR; Koo, JW; Myong, JP, 2013
)
0.39
"0 mg/kg/infusion) and a dose-response curve was generated (0."( Effects of adolescent nicotine exposure and withdrawal on intravenous cocaine self-administration during adulthood in male C57BL/6J mice.
Blaha, CD; Dickson, PE; Miller, MM; Mittleman, G; Rogers, TD, 2014
)
0.4
" Contrary to expectations derived from the self-medication hypothesis, nicotine showed no significant effects on the dependent variables, perhaps because of the dosage used and the delay between the administration of nicotine and the performance of the role-play."( Effects of nicotine on social cognition, social competence and self-reported stress in schizophrenia patients and healthy controls.
Brinkmeyer, J; Drusch, K; Fisahn, K; Lowe, A; Mobascher, A; Musso, F; Ohmann, C; Shah, J; Warbrick, T; Winterer, G; Wölwer, W, 2013
)
0.39
" The goal of this study was to determine whether cigarettes that vary in nicotine content produce an expected dose-response effect."( Dose-response effects of spectrum research cigarettes.
Denlinger, RL; Donny, E; Hatsukami, DK; Heishman, SJ; Jensen, J; Mackowick, KM; Murphy, SE; Roper-Batker, AN; Thomas, BF; Vogel, RI, 2013
)
0.39
"In the first study, significant dose-response effects were observed, particularly between the LN and HN cigarettes."( Dose-response effects of spectrum research cigarettes.
Denlinger, RL; Donny, E; Hatsukami, DK; Heishman, SJ; Jensen, J; Mackowick, KM; Murphy, SE; Roper-Batker, AN; Thomas, BF; Vogel, RI, 2013
)
0.39
" Our studies demonstrate continuity, albeit subtle, of pathologic change from high dosage experimental animal exposure to low dosage human exposures."( Correlative ultrastructural investigations of airway epithelium following experimental exposure to defined air pollutants and lifestyle exposure to tobacco smoke.
Brighton, LE; Bromberg, PA; Carson, JL; Collier, AM, 2013
)
0.39
" This effect of SHS on WBC has dose-response characteristics and should be considered to prescribing CBC."( Acute effects of second-hand smoke on complete blood count.
Dinas, PC; Flouris, AD; Jamurtas, AZ; Koutedakis, Y; Metsios, GS; Tsatsakis, AM; Tzatzarakis, MN; Wallace Hayes, A, 2014
)
0.4
" In addition, for each item of the EPDS, a dose-response pattern was revealed with non-smokers having the least risk of depressive symptoms during pregnancy and active smokers having the greatest risk."( Exposure to environmental tobacco smoke and risk of antenatal depression: application of latent variable modeling.
Bruder, K; Dagne, G; Mbah, AK; Salihu, HM; Wilson, RE, 2013
)
0.39
" Additionally, methoxsalen potentiated nicotine-induced antinociception and hypothermia as evidenced by leftward shifts in nicotine's dose-response curve."( Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
Alsharari, SD; Damaj, MI; Siu, EC; Tyndale, RF, 2014
)
0.4
" Dose-response curves for smoking versus fetal growth parameters (abscissa: log2 cotinine) were linear for biparietal diameter and femur length."( Maternal smoking during pregnancy and fetal biometry: the INMA Mother and Child Cohort Study.
Alvarez-Avellón, SM; Alvarez-Pedrerol, M; Aurrekoetxea, JJ; Ballester, F; Costa, O; Espada, M; Iñiguez, C; Murcia, M; Rebagliato, M; Santa-Marina, L; Souto, A; Vrijheid, M, 2013
)
0.39
"The dose-response relationship between the cotinine levels of the PS subjects and the number of cigarettes smoked per day was found to be significantly different for the three exposure categories."( Association of passive smoking with dental development in young children.
Avsar, A; Hazar-Bodrumlu, E; Topaloglu, B, 2013
)
0.39
" Both maternal self-reported smoking history and maternal serum cotinine levels were associated in a dose-response relationship with stillbirth."( Association between stillbirth and illicit drug use and smoking during pregnancy.
Bukowski, R; Conway, D; Coustan, D; Dudley, DJ; Goldenberg, RL; Koch, MA; Parker, CB; Pinar, H; Reddy, UM; Rowland Hogue, CJ; Saade, GR; Silver, RM; Stoll, B; Thorsten, VR; Varner, MW; Willinger, M, 2014
)
0.4
"These data provide additional evidence that opioids influence smoking and extend prior findings to include primary PO abusers, rigorous double-blind opioid dosing conditions and urinary cotinine."( Spontaneous reductions in smoking during double-blind buprenorphine detoxification.
Badger, GJ; Dunn, KE; Heil, SH; Higgins, ST; Patrick, ME; Sigmon, SC, 2014
)
0.4
"The dose-response relationship between smoking and pulmonary function in women may have been significantly over-estimated by studies that employed a self-reporting questionnaire."( Dose-related effect of urinary cotinine levels on pulmonary function among Korean women.
Jang, TW; Kim, HR; Kim, KY; Koo, JW; Lee, HE; Myong, JP; Park, CY, 2014
)
0.4
" Individual SES was strongly associated with SHS exposure in a dose-response fashion; participants in the lowest SES group were 2-3 times more likely to be exposed to SHS compared with those in the highest SES group."( Socioeconomic disparities in secondhand smoke exposure among US never-smoking adults: the National Health and Nutrition Examination Survey 1988-2010.
Gan, WQ; Jemal, A; Mannino, DM, 2015
)
0.42
" We noted an inverse relationship between smoking and fetal telomere length in a dose-response pattern (T/S ratio of nonsmokers that was more than passive smokers that was more than active smokers)."( Impact of intrauterine tobacco exposure on fetal telomere length.
King, L; Marty, PJ; Nwoga, C; Paothong, A; Pradhan, A; Salihu, HM; Whiteman, V, 2015
)
0.42
"In this study, plasma samples were obtained up to 48 h after COT was dosed to rats orally and iv at a dose of 3mg/kg."( Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.
Bartlett, MG; Beck, WD; Callahan, PM; Li, P; Terry, AV, 2015
)
0.42
"A dose-response association was observed between number of positive health characteristics and the 10-year risk of a first ASCVD event."( Health characteristics and predicted 10-year risk for a first atherosclerotic cardiovascular disease (ASCVD) event using the Pooled Cohort Risk Equations among US adults who are free of cardiovascular disease.
Loprinzi, PD; Nooe, A, 2015
)
0.42
" Dose-response relationships were quantified by Generalized Additive Models (GAMs)."( Short-term health effects in the general population following a major train accident with acrylonitrile in Belgium.
Bader, M; De Cremer, K; De Paepe, P; De Smedt, T; Fierens, S; Göen, T; Mertens, B; Nemery, B; Schettgen, T; Simons, K; Stove, C; Van Loco, J; Van Nieuwenhuyse, A; Van Overmeire, I; Van Oyen, H; Vleminckx, C, 2016
)
0.43
" A dose-response relation was observed between the CEV concentrations and the reporting of short-term health effects in the non-smokers."( Short-term health effects in the general population following a major train accident with acrylonitrile in Belgium.
Bader, M; De Cremer, K; De Paepe, P; De Smedt, T; Fierens, S; Göen, T; Mertens, B; Nemery, B; Schettgen, T; Simons, K; Stove, C; Van Loco, J; Van Nieuwenhuyse, A; Van Overmeire, I; Van Oyen, H; Vleminckx, C, 2016
)
0.43
" Hence, identifying biological and behavioral factors that modify an individual's capacity to methylate inorganic arsenic could provide insights into critical dose-response relations underlying adverse health effects."( Biological and behavioral factors modify urinary arsenic metabolic profiles in a U.S. population.
Drobna, Z; He, B; Hudgens, EE; Le, XC; Rogers, J; Styblo, M; Thomas, DJ, 2016
)
0.43
"These findings suggest that analyses of dose-response relations in arsenic-exposed populations should account for biological and behavioral factors that modify levels of inorganic and methylated arsenicals in urine."( Biological and behavioral factors modify urinary arsenic metabolic profiles in a U.S. population.
Drobna, Z; He, B; Hudgens, EE; Le, XC; Rogers, J; Styblo, M; Thomas, DJ, 2016
)
0.43
" We further built a smoking index (SI) based on these loci and demonstrated a monotonic dose-response relationship of this index with AA."( Relationship of tobacco smoking and smoking-related DNA methylation with epigenetic age acceleration.
Breitling, LP; Brenner, H; Gao, X; Zhang, Y, 2016
)
0.43
" Dose-response relationships with maternal urine cotinine concentration during pregnancy were confirmed."( Genome-wide DNA methylation study in human placenta identifies novel loci associated with maternal smoking during pregnancy.
Bollati, V; Bustamante, M; Estivill, X; Fernandez, MF; Fernandez-Tardon, G; Gallastegui, M; Llop, S; Morales, E; Motta, V; Murcia, M; Olea, N; Salas, LA; Santa-Marina, L; Sunyer, J; Tardon, A; Vilahur, N, 2016
)
0.43
"We aimed to assess the individual dose-response effects of eight maternal polymorphisms encoding polycyclic aromatic hydrocarbon-metabolizing and DNA-repair genes on prenatal cotinine levels according to infant birth size."( Modification of adverse health effects of maternal active and passive smoking by genetic susceptibility: Dose-dependent association of plasma cotinine with infant birth size among Japanese women-The Hokkaido Study.
Araki, A; Braimoh, TS; Goudarzi, H; Kishi, R; Kobayashi, S; Miyashita, C; Sasaki, S; Sata, F, 2017
)
0.46
" The dose-response relationships between Ucot concentrations and total serum IgE level were estimated using analysis of covariance (ANCOVA) and multiple linear regression analysis after adjusting for confounding variables."( Dose-Dependent Effect of Cotinine-Verified Tobacco Smoking on Serum Immunoglobulin E Levels in Korean Adult Males.
Dong, JJ; Lee, YJ; Shen, JJ, 2019
)
0.51
" We found that tobacco exposure, as measured by Ucot concentrations, increased the serum IgE levels in a dose-response manner in a representative sample of Korean adult males."( Dose-Dependent Effect of Cotinine-Verified Tobacco Smoking on Serum Immunoglobulin E Levels in Korean Adult Males.
Dong, JJ; Lee, YJ; Shen, JJ, 2019
)
0.51
"22) and related limitations, with a dose-response relationship (P < 0."( Vitamin C is not the Missing Link Between Cigarette Smoking and Spinal Pain.
Abdous, B; Desrosiers, T; Dionne, CE; Frenette, J; Laurin, D; Le Sage, N; Mondor, M; Pelletier, S, 2018
)
0.48
" Active smoking was associated with decreased serum thyrotropin (TSH) levels among both sexes, although only men exhibited a dose-response relationship between increasing smoking exposure and decreasing TSH levels."( Associations of Urinary Cotinine-Verified Active and Passive Smoking with Thyroid Function: Analysis of Population-Based Nationally Representative Data.
Choi, J; Kang, J; Kong, E, 2018
)
0.48
"Smoking status as assessed by self-reports and urine cotinine is associated with CVD risk; however, the nature of the association of urine cotinine with CVD is consistent with a dose-response relationship."( Self-Reported Smoking, Urine Cotinine, and Risk of Cardiovascular Disease: Findings From the PREVEND (Prevention of Renal and Vascular End-Stage Disease) Prospective Cohort Study.
Bakker, SJL; Dullaart, RPF; Gansevoort, RT; Kieneker, LM; Kunutsor, SK; Spee, JM; Touw, DJ; Voerman, AJ, 2018
)
0.48
"Exposome studies are challenged by exposure misclassification for non-persistent chemicals, whose temporal variability contributes to bias in dose-response functions."( Variability of urinary concentrations of non-persistent chemicals in pregnant women and school-aged children.
Andrusaityte, S; Basagaña, X; Brochot, C; Casas, M; Chatzi, L; de Bont, J; Donaire-Gonzalez, D; Giorgis-Allemand, L; Gonzalez, JR; Gracia-Lavedan, E; Granum, B; Grazuleviciene, R; Haug, LS; Kampouri, M; Lyon-Caen, S; Manzano-Salgado, CB; Pañella, P; Petraviciene, I; Philippat, C; Robinson, O; Sakhi, AK; Slama, R; Thomsen, C; Urquiza, J; Vafeiadi, M; Vernet, C; Vrijheid, M; Waiblinger, D; Wright, J; Zeman, F, 2018
)
0.48
" However, urinary cotinine levels were positively associated with incident IM in a dose-response manner in both men and women."( Smoking and Urinary Cotinine Levels Are Predictors of Increased Risk for Gastric Intestinal Metaplasia.
Ahn, J; Chang, Y; Jung, JY; Kim, K; Kim, S; Ryu, S; Sohn, CI; Yang, HJ, 2019
)
0.51
" The present study confirmed the dose-response toxic effect of tobacco smoking on chronic low-grade systemic inflammation."( Dose-Dependent Toxic Effect of Cotinine-Verified Tobacco Smoking on Systemic Inflammation in Apparently Healthy Men and Women: A Nationwide Population-Based Study.
Cho, AR; Choi, WJ; Lee, JW; Lee, YJ, 2019
)
0.51
"The study reveals an association with and a dose-response relationship between nicotine exposure during pregnancy and offspring ADHD."( Prenatal Cotinine Levels and ADHD Among Offspring.
Brown, AS; Cheslack-Postava, K; Chudal, R; Gyllenberg, D; Hinkka-Yli-Salomäki, S; Sourander, A; Sucksdorff, M; Surcel, HM, 2019
)
0.51
" Dose-response relationships between thyroid hormone (free T4, TSH, and TPO Ab) and urinary cotinine levels were estimated using ANCOVA after adjustment for all variables (age, height, weight, alcohol, exercise, and log- transformed iodine in urine)."( Impact of smoking on thyroid gland: dose-related effect of urinary cotinine levels on thyroid function and thyroid autoimmunity.
Chai, YJ; Choi, JY; Kim, MJ; Kim, SJ; Lee, KE; Myong, JP; Yoon, SG; Yu, HW, 2019
)
0.51
" Furthermore, we found that the dosage of the OAT was significantly associated with the NMR level."( Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study.
Hand, D; Kranzler, HR; Lynch, KG; Oncken, C; Schnoll, R; Tyndale, RF; Washio, Y; Zindel, LR, 2020
)
0.56
" After adjusting for potential risk factors, dose-response relationships were observed between UC risk and urinary levels of AAMA, t,t-MA, SPMA, and 8-OHdG."( Relationships among cigarette smoking, urinary biomarkers, and urothelial carcinoma risk: a case-control study.
Chang, CH; Chung, CJ; Chung, MC; Hsu, HT; Jung, WT; Kuo, YJ; Lee, HL; Li, SW; Liu, CS; Wu, GW, 2020
)
0.56
" Significant dose-response relationships between most VOC metabolites and 8-OHdG were observed."( Exposure to volatile organic compounds may be associated with oxidative DNA damage-mediated childhood asthma.
Fan, R; Jiang, W; Kuang, H; Li, Y; Li, Z; Lv, X; Pang, Q; Tan, J; Wang, Y; Wu, P; Wu, Q, 2021
)
0.62
"Among participants who reported receiving ≥3 doses of vaccine and had no antibodies indicating a history of hepatitis B infection and/or current hepatitis B infection, dose-response relationships were observed where individuals with the lowest odds of serology indicating a response to the hepatitis B vaccine (i."( Urinary polycyclic aromatic hydrocarbons concentrations and hepatitis B antibody serology in the United States (NHANES, 2003-2014).
Ahmed, SM; Andrews, FV; Kile, ML; Smit, E; Welch, BM, 2021
)
0.62
" After adjusting for covariates, SHS was associated with a 35% increased odds of HF with a dose-response relationship between levels of serum cotinine and HF."( Secondhand Smoke Exposure is Associated with Prevalent Heart Failure: Longitudinal Examination of the National Health and Nutrition Examination Survey.
Skipina, TM; Soliman, EZ; Upadhya, B, 2021
)
0.62
"There is a dose-response relationship between SHS and HF with possible effect modification by gender and prior CVD."( Secondhand Smoke Exposure is Associated with Prevalent Heart Failure: Longitudinal Examination of the National Health and Nutrition Examination Survey.
Skipina, TM; Soliman, EZ; Upadhya, B, 2021
)
0.62
" Furthermore, a dose-response relationship between serum cotinine and depressive symptoms was found in women, but not in men."( Gender differences in the associations between tobacco smoke exposure and depressive symptoms among U.S. adults: NHANES 2007-2018.
Chen, Y; Fan, Z; Gong, X; Li, L; Wang, H; Wu, L; Xu, H; Yan, C; Zeng, N, 2022
)
0.72
" The dose-response curve showed a positive nonlinear association between blood cadmium and lead levels and ED and a negative nonlinear association between blood and urinary mercury levels and ED after propensity score matching."( Associations between exposure to different heavy metals and self-reported erectile dysfunction: a population-based study using data from the 2001-2004 National Health and Nutrition Examination Survey.
Chen, M; Chen, S; Liu, C; Mao, W; Sun, C; Wu, J; Xu, B; You, Z, 2022
)
0.72
" To examine the dose-response relationships between tobacco smoke and neurological performance, we investigated whether mitochondrial DNA copy number (mtDNAcn) mediates these relationships."( Tobacco smoke exposure and mitochondrial DNA copy number on neurobehavioural performance: A community study.
Fu, M; Liu, C; Ma, Y; Nie, J; Wang, H; Wu, M, 2022
)
0.72
" Thus, we aimed to explore this relationship by focusing on dose-response relationships."( Evaluating association of smoking status during pregnancy with adverse birth outcomes using urinary cotinine concentration: The Japan environment and Children's study (JECS).
Ikeda-Araki, A; Ito, Y; Itoh, S; Kanaya, T; Kato, Y; Kishi, R; Kobayashi, S; Kunori, Y; Miyashita, C; Nagaya, K; Nakanishi, K; Saijo, Y; Sato, Y; Takahashi, S; Yoshioka, E, 2022
)
0.72
" For dose-response assessed using self-report, the odds of DOR increased significantly for every additional cigarette currently smoked (Odds ratio, OR:1."( Association between cigarette smoking and ovarian reserve among women seeking fertility care.
Ali, T; Bohler, H; Chiang, JL; Doll, MA; Gentry, A; Hein, DW; Mann, ML; Oladipupo, I; Pagidas, K; Pierson, RC; Reece, E; Taylor, KC; Torres, S, 2022
)
0.72
"This study showed that being a smoker was associated with the prevalence of OP or osteopenia compared with being a nonsmoker and that there was a strong nonlinear positive dose-response relationship between serum cotinine levels and OP and osteopenia."( Associations between smoke exposure and osteoporosis or osteopenia in a US NHANES population of elderly individuals.
Chen, S; Gu, Y; Hou, W; Zhou, Z; Zhu, C; Zhu, L, 2023
)
0.91
" Thiocyanate also displayed a better dose-response than urinary cotinine."( Validation of Urinary Thiocyanate as a Robust Biomarker of Active Tobacco Smoking in the Prospective Urban and Rural Epidemiological Study.
Britz-McKibbin, P; Gill, B; Mathiaparanam, S; Paré, G; Sathish, T; Teo, KK; Yusuf, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
biomarkerA substance used as an indicator of a biological state.
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
N-alkylpyrrolidine
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
pyrrolidine alkaloid
pyrrolidin-2-onesA pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Nicotine Pathway, Pharmacokinetics129
nicotine degradation IV428
nicotine degradation III4326
nicotine degradation II4927

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency14.96010.006038.004119,952.5996AID1159521
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID493107
GALC proteinHomo sapiens (human)Potency0.562328.183828.183828.1838AID1159614
regulator of G-protein signaling 4Homo sapiens (human)Potency16.83360.531815.435837.6858AID504845
flap endonuclease 1Homo sapiens (human)Potency6.70160.133725.412989.1251AID588795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)5,400.00000.00011.774010.0000AID241334
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)400.00000.00011.753610.0000AID1622671
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki3.00000.00000.12345.5000AID1682198
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)11,933.33330.00443.889510.0000AID1622671; AID241172
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Ki3.00000.00000.10825.5000AID1682198
Cytochrome P450 2A5Mus musculus (house mouse)IC50 (µMol)1,500.00001.00004.20259.7051AID241174
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)EC50 (µMol)21.00000.01402.272410.0000AID1682197
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)EC50 (µMol)21.00000.01402.310410.0000AID1682197
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (158)

Assay IDTitleYearJournalArticle
AID1682277Inhibition of human 5HT-7 receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076769Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 242014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1682338Inhibition of human adrenergic receptor alpha1A expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1682286Inhibition of human serotonin transporter expressed in HEK293 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076766Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relat2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1682278Inhibition of human 5HT-6 receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076764Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rel2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1682283Inhibition of human 5HT-2A receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682299Inhibition of Glutamate receptor ionotropic NMDA phencyclidine site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682268Inhibition of NOS (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1682294Inhibition of human muscarinic M1 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682276Inhibition of sigma 1 receptor (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682274Inhibition of N-type calcium channel (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1682263Inhibition of BKR2 (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1682264Inhibition of human AT1 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076765Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rela2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1682281Inhibition of human 5HT-2A receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682261Inhibition of human NK1 at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682269Inhibition of sodium channel site2 (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682310Inhibition of human dopamine transporter expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682282Inhibition of human 5HT-2C receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682288Inhibition of human delta 2-type opioid receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682289Inhibition of nAChR (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682257Inhibition of human PDE3A1A at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682304Inhibition of GABA-A agonist site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682296Inhibition of human histamine H2 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682314Inhibition of human adrenergic receptor alpha2B expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682303Inhibition of human GABA-B1 at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682316Inhibition of human adenosine transporter at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682339Inhibition of human adenosine receptor A2A expressed in HEK293 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682291Inhibition of human muscarinic M4 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682280Inhibition of 5HT-3 (unknown origin) receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682306Inhibition of human dopamine D4.4 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682266Inhibition of human CYSLTR1 expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682307Inhibition of human dopamine D2S receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682262Inhibition of human ET-A at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682336Inhibition of human adrenergic receptor alpha2A expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID242975Ratio of IC50 for human CYP2A6 to that of mouse CYP2A5 was determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1682271Inhibition of Calcium-activated potassium channel channel (unknown origin)2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682315Inhibition of human adenosine receptor A1 expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682292Inhibition of human muscarinic M2 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1682297Inhibition of human histamine H1 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682197Agonist activity at alpha4beta2 nAChR in rat frontal cortex membrane2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1682284Inhibition of 5HT-1D receptor (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682285Inhibition of human 5HT-1a receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1076775Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 22014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1076770Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24 2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1682308Inhibition of human dopamine D3 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682255Inhibition of human protein kinase A at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682267Inhibition of human BLT expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682272Inhibition of GABA receptor chloride/TBOB site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682313Inhibition of human adrenergic receptor alpha2C expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682256Inhibition of human protein kinase Ca at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682259Inhibition of acetylcholinesterase (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682337Inhibition of human adrenergic receptor alpha1B expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076761Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 0.01 uM by trypan blue exclusion assay2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1682300Inhibition of Glutamate receptor ionotropic NMDA agonist site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682305Inhibition of GABA-A alpha1 BDZ site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076771Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 22014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1076767Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rel2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1682198Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat frontal cortex membrane by scintillation counting method2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076774Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 0.1 uM by trypan blue exclusion assay2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1682258Inhibition of human PDE5A1 at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682311Inhibition of human adrenergic receptor beta2 expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID241172Inhibitory concentration against human cytochrome P450 2A62005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID1682302Inhibition of Glutamate receptor ionotropic AMPA site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682270Inhibition of human ERG in HEK293 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682279Inhibition of 5HT-4 (unknown origin) receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1076768Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rela2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1682287Inhibition of human Mu-type opioid receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682309Inhibition of human dopamine D1 receptor at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682265Inhibition of human Thromboxane A2 at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682312Inhibition of human adrenergic receptor beta1 expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682301Inhibition of Glutamate receptor ionotropic kainate site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682290Inhibition of human muscarinic M5 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682275Inhibition of sigma 2 receptor (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1076772Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 242014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1682273Inhibition of L-type calcium channel (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1682201Half life in human2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682260Inhibition of human NPY2R expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682295Inhibition of human histamine H3 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID241174Inhibitory concentration against mouse cytochrome P450 2A52005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID1682293Inhibition of human muscarinic M3 receptor expressed in CHO-K1 cells at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1682254Induction of contextual fear extinction in fear-conditioned C57/BlJ6 mouse assessed as decrease in initial freezing behavior at 5 mg/kg administered for 1 week by contextual fear conditioning assay2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID241334Inhibitory concentration against recombinant human cytochrome P450 1A22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
AID1682298Inhibition of Glutamate receptor ionotropic NMDA glycine,strychnine-sensitive site (unknown origin) at 10 uM relative to control2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,204)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990356 (8.47)18.7374
1990's756 (17.98)18.2507
2000's1172 (27.88)29.6817
2010's1488 (35.39)24.3611
2020's432 (10.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials516 (11.54%)5.53%
Reviews150 (3.35%)6.00%
Case Studies26 (0.58%)4.05%
Observational24 (0.54%)0.25%
Other3,756 (83.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]